Piper Sandler Maintains Benitec Biopharma(BNTC.US) With Buy Rating, Maintains Target Price $30
Benitec Biopharma (BNTC) Receives a Buy From Piper Sandler
Oppenheimer Maintains Benitec Biopharma(BNTC.US) With Buy Rating, Maintains Target Price $35
Benitec Biopharma Analyst Ratings
Oppenheimer Initiates Benitec Biopharma(BNTC.US) With Buy Rating, Announces Target Price $35
Benitec Biopharma Initiated With an Outperform at Oppenheimer
Leerink Partners Maintains Benitec Biopharma(BNTC.US) With Buy Rating, Raises Target Price to $20
Benitec Biopharma Is Maintained at Market Outperform by JMP Securities
Piper Sandler Maintains Benitec Biopharma(BNTC.US) With Buy Rating, Maintains Target Price $30
Piper Sandler Remains a Buy on Benitec Biopharma (BNTC)
JMP Securities Maintains Benitec Biopharma(BNTC.US) With Buy Rating, Raises Target Price to $18
Benitec Biopharma Analyst Ratings
JMP Securities Maintains Benitec Biopharma(BNTC.US) With Buy Rating, Maintains Target Price $16
Buy Rating Affirmed for Benitec Biopharma on Strong Clinical Progress and Solid Financials
Leerink Partners Maintains Benitec Biopharma(BNTC.US) With Buy Rating, Maintains Target Price $13
Leerink Partners Maintains Benitec Biopharma(BNTC.US) With Buy Rating, Maintains Target Price $13
Piper Sandler Maintains Benitec Biopharma(BNTC.US) With Buy Rating, Maintains Target Price $30
Piper Sandler Maintains Benitec Biopharma(BNTC.US) With Buy Rating, Maintains Target Price $30
Piper Sandler Sticks to Their Buy Rating for Benitec Biopharma (BNTC)
Guggenheim Initiates Benitec Biopharma(BNTC.US) With Buy Rating, Announces Target Price $17
No Data
No Data